Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

In an interview with Moneycontrol on July 14, Glenn Saldanha, Chairman and Managing Director of Glenmark, discussed the ...

CHENNAI: Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innova ...

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the ...

Get the 2025 update on the biotech companies Labiotech spotlighted in 2024 — who advanced, who stalled, and who surprised us.